Match tier Listed
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-08-15

Chenghui Li

High Impact

Associate Professor

Also affiliated: Rutgers, The State University of New Jersey (2006); Shenyang Medical College (2014); Shanghai University (2021); Zhejiang Chinese Medical University (2018–2020); University of Kentucky HealthCare (2017); Rush University Medical Center (2017); American Cancer Society (2014); Centers for Disease Control and Prevention (2014); Loyola University Medical Center (2017); Shenyang Agricultural University (2006); North China University of Science and Technology (2012); Shenyang Institute of Automation (2025); Johns Hopkins University (2017); University of Miami (2005); Tangshan College (2005); Bengbu Medical College (2022); Yanbian University (2018–2026); Chinese Academy of Sciences (2025); Nantong University (2026); Chinese Academy of Medical Sciences & Peking Union Medical College (2008); Peking University (2014); Heidelberg University (1997); Sichuan University (2025); Fudan University (2022–2025); University of Arkansas Medical Center (2011–2024); China-Japan Friendship Hospital (2008–2015); Academy of Military Medical Sciences (2018); University Medical Center (2017); Patient-Centered Outcomes Research Institute (2014); Affiliated Hospital of Nantong University (2026); University of Chicago Medical Center (2017); Zhejiang Cancer Hospital (2018–2020); Central Arkansas Veterans Healthcare System (2013–2015); Beijing Emergency Medical Center (2016); Zhongda Hospital Southeast University (2025); Zhejiang Medical and Health Group Hangzhou Hospital (2018); Analysis and Testing Centre (2025); Second People's Hospital of NanTong (2026); Miami Dermatology and Laser Institute (2005); Tangshan Normal University (2023–2025); Guang Fu Hospital (2026); Zhongshan Hospital (2022–2025); Winthrop Rockefeller Foundation (2024–2025); Anqing City Hospital (2008–2026); Chinese Academy of Agricultural Sciences (2022–2023); Cancer Hospital of Chinese Academy of Medical Sciences (2019–2020); China Academy of Railway Sciences (2009); Jiangsu University of Technology (2008–2010); Medicines Evaluation Unit (2012–2022); Ministry of Agriculture and Rural Affairs (2026); Tongji Hospital (1990); Arkansas Department of Agriculture (2016–2025); Jinhua Central Hospital (2026); University of Chinese Academy of Sciences (2019–2025); Hangzhou Cancer Hospital (2018); S.P.E.C.I.E.S. (2020); Hebei University (2012); China Agricultural University (2026); Drexel University (2013); Zhejiang University (2023); Nanjing Medical University (2022)

Faculty Researcher

Pharmacy Practice, College of Pharmacy

23 h-index 203 pubs 2,129 cited

Upstream record may be merged OpenAlex, the source of these figures, lists 62 institutions in 4 countries for this author record — a pattern that usually means it combines several researchers with similar names. The totals above may include work by other people.

  • Humans
  • Female
  • Male
  • Middle Aged
  • Aged
  • Retrospective Studies
  • Adult
  • United States
  • Adolescent
  • Young Adult
  • Animals
  • Cancer Survivors
  • Analgesics, Opioid
  • Chronic Pain
  • Breast Neoplasms

Biography and Research Information

OverviewAI-generated summary

Chenghui Li's research focuses on analyzing real-world patient data to understand disease outcomes, treatment efficacy, and health disparities. Li has investigated the survival rates of patients with non–small-cell lung cancer receiving immune checkpoint inhibitors compared to chemotherapy, particularly in older patients with brain metastases. Further research has examined rural-urban differences in patient care experiences among prostate cancer survivors, utilizing data from the SEER-CAHPS study.

Li's work also extends to the mechanisms of disease and potential therapeutic targets, as seen in studies on gastric cancer cell proliferation and invasion. Additionally, Li has contributed to research on viral infections, including the molecular detection and genetic characterization of Japanese encephalitis virus in animals and metagenomic analysis of Togaviridae in mosquito viromes. Other research areas include the association between discontinuing chronic opioid therapy and subsequent diagnoses of substance use disorders and related adverse events, using a retrospective cohort study design.

With an h-index of 23, 198 total publications, and over 2,000 citations, Li leads a research group at the University of Arkansas for Medical Sciences. Key collaborators include Bradley C. Martin, Jacob T. Painter, Mario Schootman, and Corey J. Hayes, with whom Li has co-authored multiple publications.

Metrics

  • h-index: 23
  • Publications: 203
  • Citations: 2,129

Selected Publications

  • MSR157 COMPARISON OF SAMPLING STRATEGIES TO ADDRESS SEVERE DATA IMBALANCE AND COMPUTATIONAL BENCHMARKING FOR TIME-TO-EVENT PREDICTIVE MODEL DEVELOPMENT ACROSS LOCAL AND HIGH-PERFORMANCE COMPUTING ENVIRONMENTS: PREDICTION OF ALCOHOL USE DISORDER AND OPIOID USE DISORDER AMONG ARKANSAS MEDICAL MARIJUANA CARDHOLDERS (2026)
    Value in Health DOI OpenAlex
  • HSD37 EXAMINING PATIENT AND TUMOR CHARACTERISTICS ASSOCIATED WITH THE RECEIPT OF NEOADJUVANT CHEMOTHERAPY (NAC) AMONG WOMEN WITH EARLY-STAGE HORMONE RECEPTOR-POSITIVE BREAST CANCER (2026)
    Value in Health DOI OpenAlex
  • Poverty and Mortality Risk in Patients With Colorectal Cancer (2026)
    JAMA Network Open DOI OpenAlex
  • Real-World Study Assessing Characteristics and Treatment Patterns of Patients With Human Epidermal Growth Factor Receptor 2 Immunohistochemistry 0 and Human Epidermal Growth Factor Receptor 2–Low Stage IV Breast Cancer: A Multicenter Retrospective Study (2026)
    JCO Precision Oncology DOI OpenAlex
  • Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain Metastasis (2025)
    Current Oncology DOI OpenAlex
  • The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes - insights from a single-site study (2025)
    Haematologica DOI OpenAlex
  • Impact of a minimally invasive approach for colon cancer surgery on outcomes in patients with functional limitations (2025)
    Colorectal Cancer 1 citation DOI OpenAlex
  • CO165 Effects of Pre-existing Mental Health Disorders on Endocrine Therapy Adherence in Patients with Breast Cancer (2025)
    Value in Health DOI OpenAlex
  • HPR78 Impact of the X-Waiver Elimination on Buprenorphine Prescribing by Non-Physician Clinicians: An Interrupted Time Series Analysis (2025)
    Value in Health DOI OpenAlex
  • Colorectal cancer survival disparities in persistent poverty areas (2025)
    The Journal of Rural Health 2 citations DOI OpenAlex
  • Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer (2025)
    Cancer Treatment and Research Communications DOI OpenAlex
  • Bias in Prediction Models to Identify Patients With Colorectal Cancer at High Risk for Readmission After Resection (2024)
    JCO Clinical Cancer Informatics 2 citations DOI OpenAlex
  • Investigating the coverage of the Arkansas All-Payer Claims Database for examining health disparities related to persistent poverty areas in colorectal cancer patients (2024)
    Cancer Causes & Control 1 citation DOI OpenAlex
  • Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases (2024)
    Translational Lung Cancer Research 1 citation DOI OpenAlex
  • Racial Disparity in Adherence to Endocrine Therapy among Women with Early-Stage Hormone Receptor Positive Breast Cancer: An Analysis of Arkansas All-Payers Claims Database (2024)
    Clinical Breast Cancer 1 citation DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

As listed on this researcher's institutional profile.

  • GLP-1 Based Therapies on Lymphedema in Overweight or Obese Breast Cancer Patients State of Arkansas via Arkansas Breast Cancer Research Program Principal Investigator
  • The Impact of Arkansas Medicaid Coverage Expansion and Change in Prior Authorization Procedure on Utilization of Tobacco Cessation Treatment among Ark Robert Wood Johnson Foundation Principal Investigator
  • Assessment of HER2-Low Testing Methods, Treatment Patterns and Clinical Outcomes in Advanced Breast Cancer: A Multicenter Chart Review Study AstraZeneca via University of Utah Principal Investigator
  • Affordable care act on racial disparity in endocrine therapy use among females with early stage hormone receptor positive breast cancer American Cancer Society, Inc. Principal Investigator
  • Ambulatory Resource Utilization for Gout and Gouty Arthritis Flares NOVARTIS Pharmaceuticals Corporation Principal Investigator
  • Cost-Effectiveness of Reducing Drug Treatment Barriers NIH Co-Investigator

Collaboration Network

77 Collaborators 28 Institutions 6 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics